One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Residency Match in the Virtual World
Charles C. Flippen II, MD1
doi : 10.1001/jamaneurol.2021.0428
JAMA Neurol. 2021;78(6):645-646
The Impact of Stuttering—Hiding in Plain Sight
Patrick M. Briley, PhD1; Charles Ellis Jr, PhD1; Molly M. Jacobs, PhD2
doi : 10.1001/jamaneurol.2021.0633
JAMA Neurol. 2021;78(6):646-647
A Butterfly Flaps Its Wings
Matthew Castelo, MD1,2
doi : 10.1001/jamaneurol.2021.0980
JAMA Neurol. 2021;78(6):648-649
Diversity and Disparities in Dementia Diagnosis and Care
Claudia H. Kawas, MD1,2,3; María M. Corrada, ScM, ScD1,2,4; Rachel A. Whitmer, PhD5
doi : 10.1001/jamaneurol.2021.0285
JAMA Neurol. 2021;78(6):650-652
Bariatric Surgery in Patients With Idiopathic Intracranial Hypertension—The Silver Bullet?
Deborah I. Friedman, MD, MPH1,2
doi : 10.1001/jamaneurol.2021.0364
JAMA Neurol. 2021;78(6):652-654
Women in Stroke Trials—A Tale of Perpetual Inequity in Cardiovascular Research
Safi U. Khan, MD, MS1; Erin D. Michos, MD, MHS2
doi : 10.1001/jamaneurol.2021.0624
JAMA Neurol. 2021;78(6):654-656
Assessment of Racial/Ethnic Disparities in Timeliness and Comprehensiveness of Dementia Diagnosis in California
Elena Tsoy, PhD1; Rachel E. Kiekhofer, BA1; Elan L. Guterman, MD2; Boon Lead Tee, MD1; Charles C. Windon, MD1; Karen A. Dorsman, BA3; Serggio C. Lanata, MD1,4; Gil D. Rabinovici, MD1,5,6; Bruce L. Miller, MD1,4; Amy J. H. Kind, MD, PhD7,8; Katherine L. Possin, PhD1,4
doi : 10.1001/jamaneurol.2021.0399
JAMA Neurol. 2021;78(6):657-665
The US aging population is rapidly becoming more racially and ethnically diverse. Early diagnosis of dementia is a health care priority.
Sex Disparities in Enrollment in Recent Randomized Clinical Trials of Acute Stroke
Brent Strong1; Julia Pudar, BS1; Amanda G. Thrift, PhD2; Virginia J. Howard, PhD3; Murtaza Hussain, MD1; Cheryl Carcel, MD, PhD4; Gustavo de los Campos, PhD1; Mathew J. Reeves, BVSc, PhD1
doi : 10.1001/jamaneurol.2021.0873
JAMA Neurol. 2021;78(6):666-677
The underenrollment of women in randomized clinical trials represents a threat to the validity of the evidence supporting clinical guidelines and potential disparities in access to novel treatments.
Effectiveness of Bariatric Surgery vs Community Weight Management Intervention for the Treatment of Idiopathic Intracranial Hypertension
Susan P. Mollan, MBcHB1; James L. Mitchell, MBcHB2,3; Ryan S. Ottridge, MPhil4; Magda Aguiar, PhD5; Andreas Yiangou, MBBS2,3,6; Zerin Alimajstorovic, PhD2,6,7; David M. Cartwright, MRes6,7; Olivia Grech, MRes2,6,7; Gareth G. Lavery, PhD6,7; Connar S. J. Westgate, PhD2; Vivek Vijay, MBBS2,3; William Scotton, MBBS3; Ben R. Wakerley, PhD8; Tim D. Matthews, MBcHB1; Alec Ansons, MBcHB9; Simon J. Hickman, PhD10; James Benzimra, BM, BCh11; Caroline Rick, PhD12; Rishi Singhal, MD13,14; Abd A. Tahrani, PhD6,7,15; Kristian Brock, PhD16; Emma Frew, PhD5; Alexandra J. Sinclair, PhD2,3,6
doi : 10.1001/jamaneurol.2021.0659
JAMA Neurol. 2021;78(6):678-686
Idiopathic intracranial hypertension (IIH) causes headaches, vision loss, and reduced quality of life. Sustained weight loss among patients with IIH is necessary to modify the disease and prevent relapse.
Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy
Erika A. Petersen, MD1; Thomas G. Stauss, MD2; James A. Scowcroft, MD3; Elizabeth S. Brooks, PhD4; Judith L. White, MD5; Shawn M. Sills, MD6; Kasra Amirdelfan, MD7; Maged N. Guirguis, MD8; Jijun Xu, MD, PhD9; Cong Yu, MD10; Ali Nairizi, MD11; Denis G. Patterson, DO11; Kostandinos C. Tsoulfas, MD2; Michael J. Creamer, DO12; Vincent Galan, MD13; Richard H. Bundschu, MD14; Christopher A. Paul, MD15; Neel D. Mehta, MD16; Heejung Choi, MD15; Dawood Sayed, MD17; Shivanand P. Lad, MD, PhD18; David J. DiBenedetto, MD19; Khalid A. Sethi, MD20; Johnathan H. Goree, MD15; Matthew T. Bennett, MD20; Nathan J. Harrison, MD8; Atef F. Israel, MD3; Paul Chang, MD13; Paul W. Wu, MD21; Gennady Gekht, MD14; Charles E. Argoff, MD22; Christian E. Nasr, MD23; Rod S. Taylor, PhD24; Jeyakumar Subbaroyan, PhD25; Bradford E. Gliner, MS26; David L. Caraway, MD, PhD4; Nagy A. Mekhail, MD, PhD9
doi : 10.1001/jamaneurol.2021.0538
JAMA Neurol. 2021;78(6):687-698
Many patients with diabetic peripheral neuropathy experience chronic pain and inadequate relief despite best available medical treatments.
Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis
Amber Salter, PhD1; Robert J. Fox, MD2; Scott D. Newsome, DO3; June Halper, MSCN4; David K. B. Li, MD5; Pamela Kanellis, PhD6; Kathleen Costello, MSCN7; Bruce Bebo, PhD7; Kottil Rammohan, MD8; Gary R. Cutter, PhD9; Anne H. Cross, MD1
doi : 10.1001/jamaneurol.2021.0688
JAMA Neurol. 2021;78(6):699-708
Emergence of SARS-CoV-2 causing COVID-19 prompted the need to gather information on clinical outcomes and risk factors associated with morbidity and mortality in patients with multiple sclerosis (MS) and concomitant SARS-CoV-2 infections.
Healthy Life-Year Costs of Treatment Speed From Arrival to Endovascular Thrombectomy in Patients With Ischemic Stroke
Mohammed A. Almekhlafi, MD, MSc1,2,3,4; Mayank Goyal, MD, PhD1,2,3,4; Diederik W. J. Dippel, MD5; Charles B. L. M. Majoie, MD, PhD6; Bruce C. V. Campbell, MD7; Keith W. Muir, MD8; Andrew M. Demchuk, MD1,3; Serge Bracard, MD9; Francis Guillemin, MD, PhD10; Tudor G. Jovin, MD11; Peter Mitchell, MD12; Philip White, MD13; Michael D. Hill, MD, MSc1,2,3,14; Scott Brown, PhD15; Jeffrey L. Saver, MD16; for the HERMES Trialists Collaboration
doi : 10.1001/jamaneurol.2021.1055
JAMA Neurol. 2021;78(6):709-717
The benefits of endovascular thrombectomy (EVT) are time dependent. Prior studies may have underestimated the time-benefit association because time of onset is imprecisely known.
Prevalence of Incidentally Detected Signs of Intracranial Hypertension on Magnetic Resonance Imaging and Their Association With Papilledema
Benson S. Chen, MBChB, MSc1; Benjamin I. Meyer, BS1; Amit M. Saindane, MD, MBA2; Beau B. Bruce, MD, PhD1,3; Nancy J. Newman, MD1,4,5; Valérie Biousse, MD1,4
doi : 10.1001/jamaneurol.2021.0710
JAMA Neurol. 2021;78(6):718-725
Magnetic resonance imaging (MRI) signs of intracranial hypertension (IH) are traditionally associated with idiopathic intracranial hypertension (IIH), but these signs are also detected among individuals with primary headaches and among asymptomatic individuals without papilledema.
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis
Damiano Baroncini, MD1; Marta Simone, MD2; Pietro Iaffaldano, MD3; Vincenzo Brescia Morra, MD4; Roberta Lanzillo, MD, PhD4; Massimo Filippi, MD5; Marzia Romeo, MD6; Francesco Patti, MD7; Clara Grazia Chisari, MD7; Eleonora Cocco, MD8; Giuseppe Fenu, MD8; Giuseppe Salemi, MD9; Paolo Ragonese, MD9; Matilde Inglese, MD, PhD10,11; Maria Cellerino, MD10; Lucia Margari, MD2; Giancarlo Comi, MD1,12; Mauro Zaffaroni, MD1; Angelo Ghezzi, MD1; for the Italian MS registry
doi : 10.1001/jamaneurol.2021.1008
JAMA Neurol. 2021;78(6):726-735
Availability of new disease-modifying therapies (DMTs) and changes of therapeutic paradigms have led to a general improvement of multiple sclerosis (MS) prognosis in adults. It is still unclear whether this improvement also involves patients with pediatric-onset MS (POMS), whose early management is more challenging.
Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
Arpan Patel, MD1; James Sul, MD1; Marc L. Gordon, MD2,3; Jared Steinklein, MD4; Shayna Sanguinetti, MD1; Bidyut Pramanik, MD4; Dushyant Purohit, MD5,6; Vahram Haroutunian, PhD6,7,8; Alex Williamson, MD9; Igor Koralnik, MD10; Asaff Harel, MD, MSc11
doi : 10.1001/jamaneurol.2021.0627
JAMA Neurol. 2021;78(6):736-740
Progressive multifocal leukoencephalopathy (PML) is an opportunistic infection caused by the JC virus that has no proven effective treatment. Although rare cases of PML have occurred with other anti-CD20 therapies, there had been no prior cases associated with ocrelizumab.
Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing
Elia Sechi, MD1,2; Marina Buciuc, MD1; Sean J. Pittock, MD1,3; John J. Chen, MD, PhD1,4; James P. Fryer, MS3; Sarah M. Jenkins, MS5; Adrian Budhram, MD1,6; Brian G. Weinshenker, MD1; A. Sebastian Lopez-Chiriboga, MD7; Jan-Mendelt Tillema, MD1; Andrew McKeon, MD1,3; John R. Mills, PhD3; W. Oliver Tobin, MB BCh, BAO, PhD1; Eoin P. Flanagan, MD1,3
doi : 10.1001/jamaneurol.2021.0912
JAMA Neurol. 2021;78(6):741-746
Myelin oligodendrocyte glycoprotein-IgG1–associated disorder (MOGAD) is a distinct central nervous system–demyelinating disease. Positive results on MOG-IgG1 testing by live cell-based assays can confirm a MOGAD diagnosis, but false-positive results may occur.
Sexual and Gender Minority Health in Neurology
Nicole Rosendale, MD1,2; Jeffrey O. Wong, BS3; Jason D. Flatt, PhD, MPH4; Evans Whitaker, MD, MLIS5
doi : 10.1001/jamaneurol.2020.5536
JAMA Neurol. 2021;78(6):747-754
Little is known about the neurologic health needs of sexual and gender minority (SGM) individuals, and existing research indicates health care disparities for this group.
Aneurysm-Mimicking Hemangioblastoma Presenting With Spontaneous Acute Subdural Hematoma
Roel Haeren, MD, PhD1,2; Rahul Raj, MD, PhD1; Mika Niemelä, MD, PhD1
doi : 10.1001/jamaneurol.2021.0526
JAMA Neurol. 2021;78(6):755-756
Hyoid Bone Syndrome With Sympathetic Symptoms
Rongfei Wang, MD1; Huijuan Yuan, MB1,2; Zhao Dong, MD, PhD1
doi : 10.1001/jamaneurol.2021.0750
JAMA Neurol. 2021;78(6):757-758
Electronic Cigarette Use and Cigarette-Smoking Cessation Attempts Among Stroke Survivors in the US
Neal S. Parikh, MD, MS1; Babak B. Navi, MD, MS1; Alexander E. Merkler, MD, MS1; Hooman Kamel, MD, MS1,2
doi : 10.1001/jamaneurol.2021.0636
JAMA Neurol. 2021;78(6):759-760
Assessing Brain Capillaries in Coronavirus Disease 2019
David W. Nauen, MD, PhD1; Jody E. Hooper, MD1; C. Matthew Stewart, MD, PhD2; Isaac H. Solomon, MD, PhD3
doi : 10.1001/jamaneurol.2021.0225
JAMA Neurol. 2021;78(6):760-762
Questions on NOTCH2NLC Repeat Expansions in Parkinson Disease
Wai Yan Yau, MBBS, BMedSci, MMed1; Henry Houlden, MD, PhD1; Jana Vandrovcova, PhD1
doi : 10.1001/jamaneurol.2021.0747
JAMA Neurol. 2021;78(6):762-763
Questions on NOTCH2NLC Repeat Expansions in Parkinson Disease—Reply
Dongrui Ma, PhD1; Yi Jayne Tan, BSc2; Eng-King Tan, MD1,2,3
doi : 10.1001/jamaneurol.2021.0768
JAMA Neurol. 2021;78(6):763
Risk Factors With Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy
Fujun Liu, MD1; Xin Tang, MD1; Liangxue Zhou, MD, PhD1
doi : 10.1001/jamaneurol.2021.0890
JAMA Neurol. 2021;78(6):763-764
Risk Factors With Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy—Reply
Daniel B. Rubin, MD, PhD1; Caron Jacobson, MD2; Henrikas Vaitkevicius, MD3,4
doi : 10.1001/jamaneurol.2021.0893
JAMA Neurol. 2021;78(6):764-765
